We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
-3.63%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.14B
AUM Growth
-$232M
(-9.8%)
Cap. Flow
-$62.6M
Cap. Flow
% of AUM
-2.93%
Top 10 Holdings %
Top 10 Hldgs %
61.97%
Holding
57
New
7
Increased
13
Reduced
4
Closed
8
Avg Time Held
1.3
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Erasca
ERAS
|
+$35M |
| 2 |
Disc Medicine
IRON
|
+$33M |
| 3 |
AnaptysBio
ANAB
|
+$29.5M |
| 4 |
Savara
SVRA
|
+$18.5M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$18.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alpine Immune Sciences Inc
ALPN
|
+$124M |
| 2 |
Apellis Pharmaceuticals
APLS
|
+$52M |
| 3 |
Jade Biosciences
JBIO
|
+$35.6M |
| 4 |
Structure Therapeutics
GPCR
|
+$27M |
| 5 |
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$22.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.8% |
| 2 | Miscellaneous | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
51
Jade Biosciences
JBIO
$875M
| – | – |
-34,425
| Closed | -$35.6M | – |
|
52
DELISTED
bluebird bio
BLUE
| – | – |
-85,495
| Closed | -$2.19M | – |
|
|
53
Structure Therapeutics
GPCR
$1.58B
| – | – |
-629,194
| Closed | -$27M | – |
|
54
Intellia Therapeutics
NTLA
$1.59B
| – | – |
-203,684
| Closed | -$5.6M | – |
|
55
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| – | – |
-1,030,878
| Closed | -$2.65M | – |
|
|
56
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| – | – |
-1,455,837
| Closed | -$22.9M | – |
|
|
57
DELISTED
Alpine Immune Sciences Inc
ALPN
| – | – |
-3,131,008
| Closed | -$124M | – |
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q2 2024 Portfolio in Review
As of Q2 2024, Frazier Life Sciences Management held 57 positions worth $2.14B, down 9.8% from $2.37B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Frazier Life Sciences Management's Q2 2024 filing shows 7 new, 13 increased, 4 reduced and 8 closed positions. Its largest new stake was Erasca: 16,216,216 shares worth $38.3M. The largest sale was Alpine Immune Sciences Inc, an estimated $124M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q2 2024 buy was Erasca: 16,216,216 shares worth $38.3M.
- Frazier Life Sciences Management added most to Disc Medicine in Q2 2024, an estimated $33M increase.
- Frazier Life Sciences Management's biggest Q2 2024 reduction was Merus, cutting an estimated $18.1M.
- Frazier Life Sciences Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $124M.
- Frazier Life Sciences Management's ten largest holdings make up 62% of its $2.14B portfolio in Q2 2024.
- Frazier Life Sciences Management opened 7 new positions and closed 8 in Q2 2024.
- Frazier Life Sciences Management's portfolio value fell 9.8% quarter-over-quarter to $2.14B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2024, filed 15 Aug 2024.